Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials
TL;DR Summary
Amgen's obesity drug MariTide showed significant weight loss in a Phase 2 trial but had high side effects and discontinuation rates, prompting the company to plan a slower dosing schedule for future testing.
- Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing STAT
- Monthly weight loss drug helps people lose 20% of body weight, trial finds NBC News
- Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment Yahoo Finance
- Amgen Shares Fall on Weight-Loss Drug Tummy Troubles Barron's
- ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half FirstWord Pharma
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 1 min read
Condensed
83%
198 → 33 words
Want the full story? Read the original article
Read on STAT